11/10
08:30 am
allo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Medium
Report
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
11/7
06:11 pm
allo
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]
Low
Report
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]
11/6
04:05 pm
allo
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
High
Report
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
11/3
09:04 am
allo
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
Medium
Report
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
10/30
08:30 am
allo
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
Low
Report
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
10/12
01:08 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was downgraded by analysts at
Wall S
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was downgraded by analysts at
Wall S
10/10
08:06 am
allo
Allogene Therapeutics (NASDAQ:ALLO) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
High
Report
Allogene Therapeutics (NASDAQ:ALLO) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
10/4
03:06 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at
Wall Str
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at
Wall Str
10/2
04:45 am
allo
Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]
Low
Report
Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]
9/13
01:06 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was downgraded by analysts at
Wall S
Low
Report
Allogene Therapeutics (NASDAQ:ALLO) was downgraded by analysts at
Wall S
9/12
01:35 pm
allo
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? [Yahoo! Finance]